Browsing: GLP1

Investing.com — The global obesity epidemic represents one of the most pressing public health challenges of our time. With nearly…

Investing.com — Weight-loss medications like the popular versions made by Denmark’s Novo Nordisk A/S (CSE:) and US peer Eli Lilly (NYSE:)…

In 2019, Jennifer Brown was told she had high blood sugar and was on the verge of being diagnosed with…

Eli Lilly CEO David Ricks on Tuesday quantified how much less patients taking the company’s weight-loss drug Zepbound tend to…

Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a…

Nestlé, the maker of frozen food brands like Stouffer’s and DiGiorno, is slimming down with a new line of meals…

Nestle is launching a new frozen-food brand, Vital Pursuit, aimed at the growing market of consumers who are using GLP-1…

Medifast, Inc. (NYSE:), a leading health and wellness company, reported a significant decrease in first-quarter revenue during its 2024 earnings…

GLP-1 receptor agonists are changing the way chronic conditions like type 2 diabetes are managed, but they have also been…